Share
Fred Ong
Jupiter Endovascular, Inc., an innovative medical technology company pioneering a new class of endovascular interventions, has appointed Fred Ong as Chief Financial Officer.
A seasoned executive with over 30 years of experience in healthcare technology, Ong brings deep expertise in finance, operations, and strategic growth to support Jupiter's next phase of expansion.
Throughout his career, Ong has successfully led financial operations for numerous venture-backed medtech companies, including Sirona Medical, Datavant, and U-Systems. He has played pivotal roles in driving fundraising efforts, scaling revenue, and steering strategic M&A transactions leading to successful exits. His proven leadership in financial planning and execution positions him as a key asset in accelerating Jupiter Endovascular’s mission and market impact.
Jupiter’s groundbreaking Endoportal Control™ platform aims to revolutionize catheter-based interventions by enhancing control, reach, and stability during procedures. The system allows interventionalists to access complex anatomical regions with greater precision and safety, potentially transforming the standard of care for vascular conditions.
The company recently initiated patient enrollment in a U.S. pivotal study focused on treating acute, intermediate-risk pulmonary embolism, marking a significant milestone in its clinical journey. Following its emergence from stealth in August 2024 with US$21 million in financing, the addition of Ong signals Jupiter Endovascular’s commitment to building a robust foundation for operational excellence and long-term success.
